The two programs, which issue from Affinium’s FabI discovery platform acquired by Debiopharm in February 2014, will lead to the development of narrow-spectrum antibiotics. As part of the
The trial is designed to further add to the clinical experience to date by showing the safety and tolerability of ZS-9 and its ability to restore and maintain
As part of the deal, PanAm seeks to distribute a minimum of 5,000 ‘cartons’ per month, or 150,000 pills per month, for the balance of the year with
Insys manufactures pharmaceutical dronabinol (THC) and pharmaceutical CBD at its FDA-inspected and Drug Enforcement Administration (DEA) approved facility in Round Rock, Texas. Recently, Insys submitted a drug master
As part of the deal, Sorrento will receive research fees, up-front payment, milestone payments and royalties on future net sales. Following successful attainment of key milestones, Sorrento is
The research grant will be used to study the administration of a transmucosal Lorazepam Spray for the treatment of epileptic seizures in the outpatient settings. EastGate explores drug
Xiapex is the trade name for collagenase clostridium histolyticum (CCH) in the European Union (EU). Currently, Xiapex is approved to treat Dupuytren’s contracture in adult patients with a
The double-masked, randomized sham controlled trial is designed to evaluate the safety, tolerability and pharmacokinetics of QPI-1007 in these patients. QPI-1007 is a siRNA designed drug designed to
ADXS-cHER2 is being developed to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including bone cancer (osteosarcoma), breast cancer, esophageal and gastric cancer. The company
Mersana’s Fleximer technology will be used in the development of ADCs for multiple undisclosed targets. The two firms will test a variety of ADCs by using Mersana’s platform
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.